Literature DB >> 31933762

MiR-145 inhibits cervical cancer progression and metastasis by targeting WNT2B by Wnt/β-catenin pathway.

Qi Li1, Xiaohong Yu1, Liangliang Yang1.   

Abstract

BACKGROUND: Cervical cancer is a very serious female disease worldwide, especially in developing countries. The expression level of miRNA-145 has been revealed to be decreased in various cancers, including cervical cancer. However, the molecular mechanisms by which miR-145 inhibits tumor growth and induces apoptosis in cervical cancer remain unclarified.
METHODS: The mRNA expression levels of miR-145 and WNT2B were measured by quantitative real-time polymerase chain reaction (qRT-PCR). The effect of miR-145 on cervical cancer proliferation was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Transwell assay was conducted to measure cell migration and invasion. Cell apoptosis was examined by flow cytometry assay. The target of miR-145 was predicted by online database and verified by luciferase reporter assay. In vivo experiment was employed to clarify the effect of miR-145 on tumor growth.
RESULTS: The expression level of miR-145 was down-regulated while WNT2B expression was up-regulated in cervical cancer cell tissues and cell lines. MiR-145 suppressed cell proliferation, migration and invasion, inhibited Epithelial-Mesenchymal Transition (EMT) process and induced apoptosis. We confirmed that miR-145 weakened WNT2B expression by binding with WNT2B. Furthermore, over-expression of WNT2B reversed the inhibition effects on miR-145 on proliferation and metastasis as well as promoted effects on apoptosis of cervical cells. In addition, we demonstrated that upregulation of miR-145 repressed the Wnt/β-catenin signaling pathway by repressing WNT2B expression in cervical cancer cells.
CONCLUSION: MiR-145 inhibits cervical cancer progression and metastasis through inactivating Wnt/β-catenin pathway by targeting WNT2B. IJCEP
Copyright © 2019.

Entities:  

Keywords:  WNT2B; Wnt/β-catenin signaling pathway; cervical cancer; miR-145

Year:  2019        PMID: 31933762

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  7 in total

1.  LncRNA UCA1 accelerates osteosarcoma progression via miR-145 and Wnt/β-catenin pathway.

Authors:  Jian Guan; Juliang He; Shian Liao; Zhenjie Wu; Xiang Lin; Bin Liu; Xiong Qin; Jiachang Tan; Chuangming Huang; Zhenchao Yuan; Hao Mo
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

2.  circMYC promotes cell proliferation, metastasis, and glycolysis in cervical cancer by up-regulating MET and sponging miR-577.

Authors:  Zhizhen Wang; Yang Chen; Wei Wang; Hui Wang; Ransheng Liu
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

3.  Long non-coding RNA KCNQ1OT1 facilitates the progression of cervical cancer and tumor growth through modulating miR-296-5p/HYOU1 axis.

Authors:  Jun Liu; Yingmei Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

4.  LncRNA HOTAIR facilitates high glucose-induced mesangial cell proliferation, fibrosis and oxidative stress in diabetic nephropathy via regulating miR-147a/WNT2B axis.

Authors:  Xin Wang; Wei Wang; Weizhong HuangFu; Zhonghua Liu; Feng Zhao
Journal:  Diabetol Metab Syndr       Date:  2022-02-22       Impact factor: 3.320

5.  MiR-1254 suppresses the proliferation and invasion of cervical cancer cells by modulating CD36.

Authors:  Jun Zhang; Xing Li; Jing Yang; Yan Zhang
Journal:  J Transl Med       Date:  2022-08-26       Impact factor: 8.440

Review 6.  The Role of microRNAs in the Cisplatin- and Radio-Resistance of Cervical Cancer.

Authors:  Rina Masadah; Syahrul Rauf; Muhammad Yogi Pratama; Claudio Tiribelli; Devis Pascut
Journal:  Cancers (Basel)       Date:  2021-03-09       Impact factor: 6.639

7.  Investigations on the Role of the MicroRNA-338-5p/Wnt Family Member 2B (WNT2B) Axis in Regulating the Pathogenesis of Nasopharyngeal Carcinoma (NPC).

Authors:  Suzhen Wang; Tianning Yang; Zhengxiang He
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.